Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSVTI
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HSVTI (Herpes Simplex Virus-Targeted Immunotherapy) is an investigational biological intervention developed by GlaxoSmithKline. It is designed to evaluate its safety, reactogenicity, and immunogenicity in HSV-2 seronegative individuals. The immunotherapy is administered intramuscularly and is being studied in two different formulations.
- Brand names
- HSV formulation 1
- Other names
- Herpes Simplex Virus-Targeted Immunotherapy
02
Targets
gD (HSV-2 glycoprotein D)ICP4 (Infected cell protein 4)gB (Human cytomegalovirus glycoprotein B)
Beyond the preview
Go deeper on HSVTI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSVTI.